Otsuka Pharmaceutical Development & Commercialization
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Otsuka Pharmaceutical Development & Commercialization sits in the top decile of US sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count).
Otsuka Pharmaceutical Development & Commercialization: 221 sponsored US clinical trials, 8 recruiting.
Otsuka Pharmaceutical Development & Commercialization sponsors 221 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 186 completed. 119 of these trials are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 12 trials.
Top-decile sponsor footprint
Otsuka Pharmaceutical Development & Commercialization ranks in the top decile of sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
186 of 208 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
221 total, page 4 of 5
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
NCT01395017
Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
NCT01289080
A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects
NCT01299454
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111565
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
NCT01210560
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
NCT01227512
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111539
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
NCT01122927
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
NCT01129882
Tolvaptan Extension Study in Participants With ADPKD
NCT01214421
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
NCT01009840
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
NCT01074294
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
NCT01052077
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
NCT01423903
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
NCT00948090
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder
NCT01447576
Multicenter, Open-label, Safety and Tolerability Study
NCT01649557
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
NCT00905307
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT00797966
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema
NCT00874497
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
NCT00731549
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
NCT00706654
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
NCT00705783
A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
NCT00685360
A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
NCT01870999
Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients
NCT00550459
Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT00428948
Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
NCT00365859
Aripiprazole and Effexor XR Drug Interaction Study
NCT00362271
Aripiprazole and Lexapro Drug Interaction Study
NCT00361790
Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder
NCT00321516
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
NCT00325689
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
NCT00337571
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).
NCT00332241
A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
NCT00277212
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT00413777
A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania
NCT00261443
A Study of Aripiprazole in Patients With Major Depressive Disorder
NCT00105196
Aripiprazole in Children and Adolescents With Bipolar I Disorder
NCT00110461
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
NCT00132886
Study of Aripiprazole in Patients With Acute Bipolar Mania
NCT00097266
Study of Aripiprazole in Patients With Bipolar I Disorder
NCT00257972
A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
NCT00095745
Aripiprazole Open-Label, Safety and Tolerability Study
NCT00102518
Aripiprazole in Adolescents With Schizophrenia
NCT00102063
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
NCT00094432
Aripiprazole in Patients With Acute Mania
NCT00095511
Study of Rebamipide Eye Drops to Treat Dry Eye
NCT00201955
A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a Placebo
NCT00201981
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 45 |
| Phase 3 | 109 |
| Phase 4 | 10 |
Therapeutic Areas
What is open in the Otsuka Pharmaceutical Development & Commercialization pipeline
8 recruiting of 221 indexed (4% open); 186 completed (84%).
Phase mix: 119 late (III/IV) vs 97 early (I/II) (balanced across stages).
Top condition: Schizophrenia (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Otsuka Pharmaceutical Development & Commercialization: open-pipeline peers nationwide
Peers matched on 221 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Otsuka Pharmaceutical Development & Commercialization sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 221 trials (± recruiting share)
- National Eye Institute (NEI) · 221 trials · 8% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Bausch Health Americas · 4% recruiting · 168 trials
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
Related
What to do with this Otsuka Pharmaceutical Development & Commercialization page
221 registered trials is a research-attention snapshot, not an endorsement of Otsuka Pharmaceutical Development & Commercialization or any single study.
- 8 of Otsuka Pharmaceutical Development & Commercialization's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Otsuka Pharmaceutical Development & Commercialization studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Otsuka Pharmaceutical Development & Commercialization pipeline card: 221 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.